Replies to post #122162 on Biotech Values

[DewDiligence]

PARD/Allozyne quit trying to make an eagle out of two turkeys:

http://finance.yahoo.com/news/Poniard-Pharmaceuticals-iw-902099746.html?x=0

The termination follows the parties' determination that the common stock of the combined company resulting from the proposed merger will not qualify for listing on The Nasdaq Capital Market…

It’s pretty funny that a non-listing on Nasdaq is enough to defeat the purported business rationale for the merger. Corollary: There was no bona fide business rationale for this merger.